Synaptogenix Inc (SNPX)

[SF Wolf]

The 10Q clearly states non-memantine positive results in 20ug patients:

If NTRP gets similar results in the Confirmatory P2 it is going to represent a major breakthrough in AD treatment (with implications for many other cognitive disorders)

At week 15, non-memantine patients in the mITT Group treated with 20 µg (n=14) showed an SIB improvement of 5.88, while the placebo patients (n=11) showed a decline in their SIB scores of -0.05 for an overall treatment ? of 5.93 from baseline (p=0.0576).


At week 15, non-memantine patients in the Completers Group treated with 20 µg (n=14) showed an SIB improvement of 6.24, while the placebo patients (n=11) showed a decline in their SIB scores of -0.12 for an overall treatment ? of 6.36 from baseline (p=0.0488).


Patients taking memantine as background therapy in the 20 µg (n=20) and control (n=22) groups showed no improvement in SIB scores.

https://last10k.com/sec-filings/ntrp/0001144204-19-024943.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=ntrp#link_fullReport